Ed Esplin, SVP of Medical Affairs at Biocartis, shared on LinkedIn:
”Longitudinal outcome analysis indicates that prostate cancer patients carrying African-specific HOXB13 stop-loss germline variant X285K generally show favorable responses to therapies targeting the androgenreceptor (AR).
X285K germline variant could be another biomarker forecasting a generally better outcome to AR-targeted therapies in metastatic Hormone Sensitive Prostate Cancer/ mHSPC.
One more reason for universal germline genetictesting in all patients with prostate cancer.”
Title 1: Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant
Authors: Mayuko Kanayama, Emeline Colomba, Yusra Shao, Sarah M. Nielsen, Edward D. Esplin, Changxue Lu, William B. Isaacs, John C. Henegan, Elisabeth I. Heath, Jun Luo, Régine Marlin, Emmanuel S. Antonarakis
Title 2: Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Authors: Neal Shore, Sarah M. Nielsen, Edward D. Esplin, Emmanuel S. Antonarakis, Pedro C. Barata, Tomasz M. Beer, Himisha Beltran, Alan Bryce, Michael S. Cookson, E. David Crawford, Tanya B. Dorff, Daniel J. George, Elisabeth I. Heath, Brian T. Helfand, Maha Hussain, Rana R. Mckay, Alicia K. Morgans, Michael J. Morris, Channing J. Paller, Ashley E. Ross, Oliver Sartor, John Shen, Paul Sieber, Matthew R. Smith, David R. Wise, Andrew J. Armstrong
Other articles featuring Ed Esplin on OncoDaily.
